ARTICLE | Finance
Aeglea's crossover
How Aeglea's B round could set the company up for a future IPO
March 30, 2015 7:00 AM UTC
The series B syndicate assembled by Aeglea Biotherapeutics Inc. has the hallmarks of a pre-IPO round. With a lead therapeutic enzyme on the brink of entering the clinic for Orphan diseases and cancer metabolism, the company has brought in a troop of new crossover investors.
The $44 million round was led by existing investors Lilly Ventures and Novartis Venture Fund. Existing investor UT Horizon Fund also participated, along with new investors OrbiMed, Jennison Associates, Venrock, RA Capital Management, Rock Springs Capital, Ally Bridge Group and Cowen Investments...